Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models

IntroductionEx vivo experiments in extracorporeal membrane oxygenation (ECMO) circuits have identified octanol-water partition coefficient (logP, a marker of lipophilicity) and protein binding (PB) as key drug factors affecting pharmacokinetics (PK) during ECMO. Using ovine models, in this study we investigated whether these drug properties can be used to predict PK alterations of antimicrobial drugs during ECMO.MethodsSingle-dose PK sampling was performed in healthy sheep (HS, n = 7), healthy sheep on ECMO (E24H, n = 7) and sheep with smoke inhalation acute lung injury on ECMO (SE24H, n = 6). The sheep received eight study antimicrobials (ceftriaxone, gentamicin, meropenem, vancomycin, doripenem, ciprofloxacin, fluconazole, caspofungin) that exhibit varying degrees of logP and PB. Plasma drug concentrations were determined using validated chromatographic techniques. PK data obtained from a non-compartmental analysis were used in a linear regression model to predict PK parameters based on logP and PB.ResultsWe found statistically significant differences in pH, haemodynamics, fluid balance and plasma proteins between the E24H and SE24H groups (p < 0.001). logP had a strong positive linear relationship with steady-state volume of distribution (Vss) in both the E24H and SE24H groups (p < 0.001) but not in the HS group (p = 0.9) and no relationship with clearance (CL) in all study groups. Although we observed an increase in CL for highly PB drugs in ECMO sheep, PB exhibited a weaker negative linear relationship with both CL (HS, p = 0.01; E24H, p < 0.001; SE24H, p < 0.001) and Vss (HS, p = 0.01; E24H, p = 0.004; SE24H, p =0.05) in the final model.ConclusionsLipophilic antimicrobials are likely to have an increased Vss and decreased CL during ECMO. Protein-bound antimicrobial agents are likely to have reductions both in CL and Vss during ECMO. The strong relationship between lipophilicity and Vss seen in both the E24H and SE24H groups indicates circuit sequestration of lipophilic drugs. These findings highlight the importance of drug factors in predicting antimicrobial drug PK during ECMO and should be a consideration when performing and interpreting population PK studies.

[1]  J. Vincent,et al.  Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study , 2014, Critical Care.

[2]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[3]  M. Buck Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation , 2003, Clinical pharmacokinetics.

[4]  D. Kaufman,et al.  Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults* , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[5]  Frédérique Jacobs,et al.  β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study. , 2015, International journal of antimicrobial agents.

[6]  J. Fraser,et al.  The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[8]  J. Fraser,et al.  Effect of smoke inhalation on viscoelastic properties and ventilation distribution in sheep. , 2006, Journal of applied physiology.

[9]  P. Hinderling,et al.  The pH Dependency of the Binding of Drugs to Plasma Proteins in Man , 2005, Therapeutic drug monitoring.

[10]  H. Neumayer,et al.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease , 1984, European Journal of Drug Metabolism and Pharmacokinetics.

[11]  J. J. Fins,et al.  Extracorporeal membrane oxygenation for ARDS in adults. , 2012, The New England journal of medicine.

[12]  S. Chauhan,et al.  Extracorporeal membrane oxygenation, an anesthesiologist's perspective: physiology and principles. Part 1. , 2011, Annals of cardiac anaesthesia.

[13]  Kiran Shekar,et al.  Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation , 2012, Critical Care.

[14]  W. Butt,et al.  Extracorporeal membrane oxygenation and sepsis. , 2007, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[15]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[16]  Kiran Shekar,et al.  The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study , 2014, Critical Care.

[17]  O. Cars,et al.  Protein Binding: Do We Ever Learn? , 2011, Antimicrobial Agents and Chemotherapy.

[18]  D. Pilcher,et al.  Infections Acquired by Adults Who Receive Extracorporeal Membrane Oxygenation Risk Factors and Outcome , 2013, Infection Control & Hospital Epidemiology.

[19]  J. Fraser,et al.  Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. , 2012, Journal of critical care.

[20]  Kiran Shekar,et al.  ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO , 2012, BMC Anesthesiology.

[21]  J. Fraser,et al.  Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study , 2015, Critical Care.

[22]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[23]  Bruce Thomson,et al.  Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review , 2014, Critical Care.

[24]  D. Brodie,et al.  Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. , 2014, Journal of the American College of Cardiology.

[25]  A. Combes,et al.  Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza , 2012, Therapeutic drug monitoring.

[26]  T F Blaschke,et al.  Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation , 1990, The Pediatric infectious disease journal.

[27]  David Stewart,et al.  Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. , 2012, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[28]  Ryan P. Barbaro,et al.  Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. , 2015, American journal of respiratory and critical care medicine.

[29]  Kiran Shekar,et al.  The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation , 2013, BMC Anesthesiology.

[30]  D. Paterson,et al.  Antibiotic resistance—What’s dosing got to do with it? , 2008, Critical care medicine.

[31]  K. Shekar Extracorporeal Respiratory Support: Breaking Conventions? , 2014, Anaesthesia and intensive care.